Norris Medicines' Financial Results Show Resilience

Nov 11 2023 12:00 AM IST
share
Share Via
Norris Medicines has reported a 169.47% increase in net sales and a 21.31% growth in standalone net profit for the quarter ended September 2023, despite challenges faced by the pharmaceutical industry due to the pandemic. The company's operating profit and interest expenses also showed positive trends, indicating efficient management. MarketsMojo may have given a 'Sell' call, but Norris Medicines has shown resilience and potential for growth.
The pharmaceutical industry has been facing challenges due to the ongoing pandemic, but Norris Medicines has managed to show a positive growth in their financial results for the quarter ended September 2023. The company has reported a 169.47% increase in net sales compared to the previous quarter, which was at -21.49%. This is a significant improvement and shows the company's resilience in the face of adversity.

The standalone net profit for the quarter also saw a growth of 21.31%, compared to a decline of -12.96% in the previous quarter. This is a positive sign for the company and its investors. The operating profit (PBDIT) excluding other income also saw a growth of 35.90%, which is a significant improvement from the -170.91% decline in the previous quarter.

The company's interest expenses remained flat, showing no change from the previous quarter. However, the operating profit margin (excluding other income) has improved from the previous quarter, indicating better management of expenses and operations.

MarketsMOJO has given a 'Sell' call for Norris Medicines' stock, but the company's financial results for the quarter ended September 2023 show a positive growth trend. This is a promising sign for the company's future and its investors. With a microcap size, Norris Medicines has shown resilience and potential for growth in the pharmaceutical industry.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News